| 期刊全称 | Advanced Nanobiomed Research | ||||||||||||||||||||||||||||||||
| 期刊缩写 | |||||||||||||||||||||||||||||||||
| 温馨提示 | （此期刊未被最新的JCR期刊引证报告收录） | ||||||||||||||||||||||||||||||||
|
涉及主题
（科研通AI识别） |
|||||||||||||||||||||||||||||||||
| 期刊介绍 | Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science. The scope of Advanced NanoBiomed Research will cover the following key subject areas: ▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging. ▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications. ▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture. ▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs. ▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization. ▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems. with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies. | ||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||
| 期刊ISSN | print: 2699-9307 | ||||||||||||||||||||||||||||||||
| 2023最新影响因子 (2024年6月20日公布) 与上一年的差值 |
4↑ 0.6 | ||||||||||||||||||||||||||||||||
| 历年影响因子 |
|
||||||||||||||||||||||||||||||||
| 历年发表/被引量 （科研通AI通过大数据分析） 最后更新日期：2025-04-24 |
|
||||||||||||||||||||||||||||||||
| h-index（2021） | 暂无h-index数据 | ||||||||||||||||||||||||||||||||
| 自引率 | 2.50% | ||||||||||||||||||||||||||||||||
| 涉及的研究领域 | nanomedicine, bioengineering and biomaterials- | ||||||||||||||||||||||||||||||||
| 中科院2025年分区 （2025年3月20日发布） |
|
||||||||||||||||||||||||||||||||
| WOS期刊分区 （2024年6月20日公布） |
JCR学科分类
JCI学科分类
|
||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2023年12月升级版） |
暂无 | ||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2022年12月升级版） |
暂无 | ||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月基础版） |
暂无 | ||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月升级版） |
暂无 | ||||||||||||||||||||||||||||||||
| 中科院《国际期刊预警名单（试行）》名单 |
2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 |
||||||||||||||||||||||||||||||||
| 期刊主页 | |||||||||||||||||||||||||||||||||
| 投稿网址 | https://www.editorialmanager.com/advnanobiomedres/ | ||||||||||||||||||||||||||||||||
| 编辑部地址 | Postfach 10 11 61 69451 Weinheim Germany | ||||||||||||||||||||||||||||||||
| 出版商 | Wiley-VCH, Germany | ||||||||||||||||||||||||||||||||
| 出版国家（地区） | Germany | ||||||||||||||||||||||||||||||||
| 出版语言 | English | ||||||||||||||||||||||||||||||||
| 出版周期 | |||||||||||||||||||||||||||||||||
| 每年出版文章数 | 0 | ||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 79.60% | ||||||||||||||||||||||||||||||||
| 原创研究文献占比 （排除综述） |
59.82% | ||||||||||||||||||||||||||||||||
| SCI收录类型 | 暂无 | ||||||||||||||||||||||||||||||||
| PubMed链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2699-9307%5BISSN%5D | ||||||||||||||||||||||||||||||||
| 平均审稿周期 | 网友分享经验： average 21 weeks |
||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： |
||||||||||||||||||||||||||||||||
| 相关链接 |
LetPub
您可以在上述网站查看该期刊的网友互动，及期刊影响力的其它指标。
|
||||||||||||||||||||||||||||||||
皖公网安备34019202002308
